Figure 2.

The association between TGFBR2 mutation and survival of immune checkpoint inhibitors in the training cohort. (a) Kaplan–Meier survival curves of PFS comparing the TGFBR2 mutation group and TGFBR2 wide-type group treated with immunotherapy. (b) Kaplan–Meier survival curves of OS comparing the TGFBR2 mutation group and TGFBR2 wide-type group treated with immunotherapy. (c) Kaplan–Meier survival curves of PFS comparing the TGFBR2 mutation group and TGFBR2 wide-type group treated with chemotherapy. (d) Kaplan–Meier survival curves of OS comparing the TGFBR2 mutation group and TGFBR2 wide-type group treated with chemotherapy. (e) OncoPrint depicts mutated genes with prevalence >20% in TGFBR2 mutation group. Reported frequencies include a composite of missense, nonsense, and splice mutations for each gene. Horizontal ordinate represents the mutation frequencies across different genes. Summary rows of each case at top include annotation for total number of mutations, age, sex, histology, smoking status and treatment. Patients without gene mutations are depicted in light gray on the OncoPrint. (f) Comparison of blood tumor mutational burden between TGFBR2 mutation group and TGFBR2 wide-type group treated with immunotherapy (g) Comparison of PD-L1 expression between TGFBR2 mutation group and TGFBR2 wide-type group treated with immunotherapy.

PD-L1, programmed death-ligand 1; PFS, progression free survival; TGFBR2, transforming growth factor β receptor 2.